 Connection
Charles Edelstein to Polycystic Kidney, Autosomal Dominant
This is a "connection" page, showing publications Charles Edelstein has written about Polycystic Kidney, Autosomal Dominant.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.509 |
|
|
|
-
Atwood D, He Z, Miyazaki M, Hailu F, Klawitter J, Edelstein CL. Early treatment with 2-deoxy-d-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (PKD). Cell Signal. 2024 11; 123:111351.
Score: 0.664
-
Oto OA, Edelstein CL. The Pathophysiology of Left Ventricular Hypertrophy, beyond Hypertension, in Autosomal Dominant Polycystic Kidney Disease. Nephron. 2024; 148(4):215-223.
Score: 0.576
-
Atwood DJ, Brown CN, Holditch SJ, Pokhrel D, Thorburn A, Hopp K, Edelstein CL. The effect of trehalose on autophagy-related proteins and cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Cell Signal. 2020 11; 75:109760.
Score: 0.505
-
Atwood DJ, Pokhrel D, Brown CN, Holditch SJ, Bachu DM, Thorburn A, Hopp K, Edelstein CL. Increased mTOR and suppressed autophagic flux in the heart of a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Cell Signal. 2020 10; 74:109730.
Score: 0.502
-
Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspa M, Hopp K, Weiser-Evans MCM, Edelstein CL. The consequences of increased 4E-BP1 in polycystic kidney disease. Hum Mol Genet. 2019 12 15; 28(24):4132-4147.
Score: 0.480
-
Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 07 01; 317(1):F187-F196.
Score: 0.460
-
Davis S, Gralla J, Chan L, Wiseman A, Edelstein CL. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study. Transplant Proc. 2018 Jun; 50(5):1243-1248.
Score: 0.432
-
Ravichandran K, Ozkok A, Wang Q, Mullick AE, Edelstein CL. Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2. Am J Physiol Renal Physiol. 2015 Feb 15; 308(4):F349-57.
Score: 0.340
-
Belibi F, Ravichandran K, Zafar I, He Z, Edelstein CL. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol. 2011 Jan; 300(1):F236-44.
Score: 0.254
-
Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 2010 Oct; 78(8):754-61.
Score: 0.251
-
Doctor RB, Serkova NJ, Hasebroock KM, Zafar I, Edelstein CL. Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice. Nephrol Dial Transplant. 2010 Nov; 25(11):3496-504.
Score: 0.246
-
Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs. 2010 Mar; 19(3):315-28.
Score: 0.244
-
Belibi FA, Edelstein CL. Unified ultrasonographic diagnostic criteria for polycystic kidney disease. J Am Soc Nephrol. 2009 Jan; 20(1):6-8.
Score: 0.224
-
Edelstein CL. Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol News Issues. 2008 Mar; 22(3):25-6.
Score: 0.212
-
Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007 Sep; 293(3):F854-9.
Score: 0.202
-
Tao Y, Kim J, Stanley M, He Z, Faubel S, Schrier RW, Edelstein CL. Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD). Kidney Int. 2005 Mar; 67(3):909-19.
Score: 0.172
-
Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005 Jan; 16(1):46-51.
Score: 0.169
-
Bjornstad P, Richard G, Choi YJ, Nowak KL, Steele C, Chonchol MB, Nadeau KJ, Vigers T, Pyle L, Tommerdahl K, van Raalte DH, Hilkin A, Driscoll L, Birznieks C, Hopp K, Wang W, Edelstein C, Nelson RG, Gregory AV, Kline TL, Blondin D, Gitomer B. Kidney Energetics and Cyst Burden in Autosomal Dominant Polycystic Kidney Disease: A Pilot Study. Am J Kidney Dis. 2024 09; 84(3):286-297.e1.
Score: 0.162
-
Ecder T, Melnikov VY, Stanley M, Korular D, Lucia MS, Schrier RW, Edelstein CL. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int. 2002 Apr; 61(4):1220-30.
Score: 0.141
-
Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, Zeltner R, Tian X, Grantham JJ, Somlo S. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012 Apr; 81(8):784-90.
Score: 0.069
-
Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, Edelstein CL. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A. 2005 May 10; 102(19):6954-9.
Score: 0.044
-
Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9.
Score: 0.036
-
Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001 Mar-Apr; 21(2):98-103.
Score: 0.033
-
Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Duley IT, Gabow PA, Schrier RW. Progress in blood pressure control in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000 Aug; 36(2):266-71.
Score: 0.031
-
Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000 Mar; 35(3):427-32.
Score: 0.030
-
Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999 May; 14(5):1113-6.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|